Parmax Pharma promoters acquire 22.8 lakh shares in preferential issue
- Parmax Pharma promoters acquired 22,80,444 equity shares and 17,16,574 warrants via preferential allotment
- The issue price was ₹36.50 per share/warrant, raising ₹11.45 crore from the equity component
- Promoter group holding rose to 68.34% on a fully diluted basis from 58.01%
- Remaining shares and warrants were allotted to public shareholders
*this image is generated using AI for illustrative purposes only.
Parmax Pharma Limited promoters and persons acting in concert (PACs) acquired 22,80,444 equity shares and 17,16,574 convertible warrants through a preferential allotment. The acquisition was disclosed under Regulation 29(2) of the SEBI Takeover Regulations on September 1, 2026.
The Board had sanctioned the issue on August 29, 2026, at an issue price of ₹36.50 per share or warrant. The transaction raises ₹11,45,21,889 from the equity component alone. The Company received in-principle approval from the Stock Exchange on August 21, 2026.
Acquisition Details
The acquirers include Dhiren Chandulal Shah and Sunil Chinubhai Shah as primary acquirers. Ten individuals are classified as PACs, including Dhairya Dhiren Shah, Hiren Pravin Doshi, Sheetal Hiren Doshi, Nirmal Sunilbhai Shah, Rupa Sunil Shah, Vijaykumar Natvarlal Shiyani, Kamlesh Natvarlal Shiyani, Abhay Chinubhai Shah, Umang Alkesh Gosalia, and Meena Alkesh Gosalia.
Out of the total 31,37,586 equity shares issued, the promoter group acquired 22,80,444 shares. The remaining 8,57,142 equity shares were allotted to other public shareholders. Similarly, out of 21,45,145 warrants issued, the promoter group received 17,16,574 warrants, with the remaining 4,28,571 allotted to public shareholders.
| Security Type | Total Issued | Acquired by Promoters/PACs | Acquired by Public Shareholders |
|---|---|---|---|
| Equity Shares | 31,37,586 | 22,80,444 | 8,57,142 |
| Convertible Warrants | 21,45,145 | 17,16,574 | 4,28,571 |
Promoter Holding Structure
Before the acquisition, the promoter group held 21,70,164 equity shares, representing 58.01% of the total voting capital. Following the preferential allotment, their holding in equity shares increased to 44,50,608, or 49.32% of the expanded voting capital.
Including the warrants, the total diluted holding of the promoter group stands at 61,67,179 instruments, representing 68.34% of the total diluted share capital. The total diluted share capital is calculated at 90,24,031 shares, assuming full conversion of outstanding warrants.
Allotment Structure
The preferential issue targets members of the non-promoter category who transitioned to the promoter group. The equity shares allotted rank pari-passu with existing shares. The warrants are fully convertible into one equity share each within 18 months.
| Security Type | Quantity | Issue Price | Conversion Period |
|---|---|---|---|
| Equity Shares | 31,37,586 | ₹36.50 | Not Applicable |
| Convertible Warrants | 21,45,145 | ₹36.50 | 18 months |
Promoter Status Changes
Several allottees transitioned from the non-promoter (public) category to the promoter group following the allotment. Dhiren Chandulal Shah, Sunil Chinubhai Shah, Hiren Pravin Doshi, and Umang Alkesh Gosalia were reclassified as promoters.
Other individuals, including Sheetal Hiren Doshi and Nirmal Sunilbhai Shah, joined the promoter group. Urvi Manish Kothari, Mili Saumil Shah, and Fredun Nariman Medhora remained in the non-promoter category.
What the Numbers Show
The preferential issue significantly consolidates promoter control. The promoter group’s stake increased from 58.01% to 68.34% on a fully diluted basis. This indicates a strong commitment from the existing management and family groups to fund the company’s growth initiatives without diluting their control significantly relative to public shareholders.
How will the ₹11.45 crore raised from this preferential allotment be specifically allocated across Parmax Pharma's growth initiatives or debt reduction?
What is the expected impact on Parmax Pharma's stock price volatility once the 21.45 lakh convertible warrants enter the market for conversion within the next 18 months?
Will the reclassification of key individuals like Dhiren Chandulal Shah and Sunil Chinubhai Shah to promoter status alter the company's corporate governance structure or decision-making dynamics?
17
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
